Turkey sets 91.25% Chinese vaccine efficacy rate in study

Turkey said a study involving thousands of volunteers showed an estimated efficiency rate of 91.25% for the Chinese-made Covid-19 vaccine. Nephew of Biotech Ltd., a far higher level than proposed in a shooting study in Brazil.

Since September, Turkey has led trials involving more than 3,400 people, according to a press conference by Health Minister Fahrettin Koce. The efficiency rate was determined between about half of the participants, he said.

Earlier, Brazil said the clinical trial showed that the vaccine against the sons was more than 50% effective, although the researchers delayed publishing more information at the request of the company.

Turkey has agreed to buy 50m doses of the Sinovac vaccine, with the first shipments expected on Sunday. Authorities will soon begin a four-phase vaccination program, giving preference to medical staff, people over the age of 65 who have chronic illnesses, and people with physical disabilities.

Koca said that the vaccine against Sinovac is desirable, because it is produced by conventional methods. However, Turkey is in early negotiations to receive about 4.5 million doses of the vaccine it produced Pfizer Inc. and partner BioNTech by the end of March, Koca said. The Pfizer-BioNTech vaccine was developed using messenger RNA technology, a new anti-virus strategy.